AI Terminal
Ion Beam Applications, SA
Transaction in Own Shares • Jul 9, 2021
3960_dirs_2021-07-09_0e722b3e-f284-4fc0-a04b-83da33916966.pdf
Transaction in Own Shares
Open in ViewerOpens in native device viewer
IBA – ACQUISITION OF OWN SHARES
Immediate Release – July 9 th, 2021
Louvain-la-Neuve, Belgium, July 9 th , 2021 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA ("IBA") hereby discloses information in relation to its share buyback program announced on June 29th, 2021.
Under this program, IBA has requested a financial intermediary to repurchase up to 250.000 IBA ordinary shares on its behalf under the terms of a discretionary mandate agreement with validity until December 30 th , 2021, effective as from June 30th, 2021, to cover the company's obligations under a long term incentive plan for certain members of its personnel.
In the framework of this share buyback program, IBA repurchased 18.793 IBA shares on Euronext Brussels in the period from June 30th , 2021 up to and including July 8 th , 2021, as follows:
| Trade date | Shares purchased |
Average price |
Min price | Max price | Buyback amount |
|---|---|---|---|---|---|
| 30-06-21 | 1.215 | 16,48 € | 16,40 € | 16,54 € | 20.017,13 € |
| Bloc 30/06 | 5.000 | 16,48 € | 16,48 € | 16,48 € | 82.400,00 € |
| 01-07-21 | 2.014 | 16,50 € | 16,32 € | 16,62 € | 33.233,22 € |
| 02-07-21 | 2.118 | 16,53 € | 16,46 € | 16,64 € | 35.013,72 € |
| 05-07-21 | 1.057 | 16,65 € | 16,60 € | 16,68 € | 17.595,24 € |
| 06-07-21 | 2.247 | 16,45 € | 16,36 € | 16,52 € | 36.966,97 € |
| 07-07-21 | 1.654 | 16,60 € | 16,50 € | 16,74 € | 27.455,08 € |
| 08-07-21 | 3.488 | 16,32 € | 16,06 € | 16,50 € | 56.910,21 € |
| TOTAL | 18.793 | 16,47 € | 16,06 € | 16,74 € | 309.591,56 € |
These transactions include the purchase of a block of 5.000 shares at a price of 16,48 EUR/share, which was executed on June 30 th, 2021 at 10.32 AM on the central order book of Euronext Brussels (XBRU).
The total number of shares purchased under this program therefore amounts to 18.793. As a result, IBA SA currently holds 839.665 treasury shares (directly and indirectly through its subsidiary IBA Investments SCRL), representing 2,79% of its share capital.
Press release |
About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.
IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at www.iba-worldwide.com
Press release |
Press release
Inside / regulated information
Contact person IBA Christian Matton, Chief Legal Officer [email protected]
Press release |
IBA | Ion Beam Applications Chemin du Cyclotron, 3 | 1348 Louvain-la-Neuve | Belgium | RPM Nivelles | VAT BE0428.750.985 T +32 10 47 58 11 | F +32 10 47 58 10 | [email protected] | iba-worldwide.com
